Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 20, 2020 - Issue 3
Submit an article Journal homepage
155
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Cost-minimization analysis between intravenous iron sucrose and iron sucrose similar in hemodialysis patients

Arnaud Pagèsa Department of Pharmacy, CHU de Toulouse, Toulouse, France;b UMR 1027, Inserm UPS Université de Toulouse III, Toulouse, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2337-8693View further author information
ORCID Icon,
Céline Porteilsa Department of Pharmacy, CHU de Toulouse, Toulouse, FranceView further author information
,
Isabelle Labadensa Department of Pharmacy, CHU de Toulouse, Toulouse, FranceView further author information
,
Matthieu Parmiera Department of Pharmacy, CHU de Toulouse, Toulouse, FranceView further author information
,
Samantha Osesa Department of Pharmacy, CHU de Toulouse, Toulouse, FranceView further author information
,
Damien Semelya Department of Pharmacy, CHU de Toulouse, Toulouse, FranceView further author information
,
Marion Bourdonclea Department of Pharmacy, CHU de Toulouse, Toulouse, FranceView further author information
,
Bruno Seigneuricc Department of Nephrology, Dialysis and Organ Transplantation, CHU de Toulouse, Toulouse, FranceView further author information
,
Arnaud Del Belloc Department of Nephrology, Dialysis and Organ Transplantation, CHU de Toulouse, Toulouse, FranceView further author information
&
Blandine Juillard-Condata Department of Pharmacy, CHU de Toulouse, Toulouse, France;b UMR 1027, Inserm UPS Université de Toulouse III, Toulouse, FranceView further author information
 show all
Pages 281-287 | Received 07 Feb 2019, Accepted 12 Jun 2019, Published online: 01 Jul 2019

References

  • Babitt JL, Lin HY. Mechanisms of anemia in CKD. J. Am. Soc. Nephrol. JASN. 2012;23:1631–1634.
  • Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PloS One. 2015;10:e0117383.
  • KDIGO Board Members. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. Suppl. 2012;64:279–335.
  • Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2016;68:677–690.
  • Barot BS, Parejiya PB, Mehta DM, et al. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study. Pharm. Dev. Technol. 2014;19:513–520.
  • European Medicine Agency (EMA), Committee for Medicinal Products for human use (CHMP). Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. 2011.
  • Food and Drug Administration (FDA). Draft guidance on iron sucrose bioequivalence. 2013.
  • Schellekens H, Klinger E, Mühlebach S, et al. The therapeutic equivalence of complex drugs. Regul. Toxicol. Pharmacol. 2011;59:176–183.
  • Toblli JE, Cao G, Oliveri L, et al. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Drug Res. 2009;59:176–190.
  • Toblli JE, Cao G, Oliveri L, et al. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm. Allergy-Drug Targets Former. Curr. Drug Targets-Inflamm. Allergy. 2012;11:66–78.
  • Toblli JE, Cao G, Oliveri L, et al. Differences between the original iron sucrose complex Venofer® and the iron sucrose similar Generis®, and potential implications. Port J Nephrol Hypert. 2009;23:53–63.
  • Rottembourg J, Kadri A, Leonard E, et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol. Dial. Transplant. 2011;26:3262–3267.
  • Agüera ML, Martin-Malo A, Alvarez-Lara MA, et al. Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis. PloS One. 2015;10:e0135967.
  • French Public Drugs Database. Venofer (iron sucrose) - Summary of Product Characteristics [Internet]. [cited 2019 Jun 7]. Available from: http://base-donnees-publique.medicaments.gouv.fr/.
  • Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Value Health. 2013;16:e1–e5.
  • European Medicines Agency. Aranesp | Summary Of Product Characteristics [Internet]. [ cited 2019 Jan 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/aranesp#product-information-section.
  • Donck J, Gonzalez-Tabares L, Chanliau J, et al. Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study. Adv. Ther. 2014;31:1155–1168.
  • Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus. 2009;2:i9–i17.
  • Choi P, Farouk M, Manamley N, et al. Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study. Adv. Ther. 2013;30:1007–1017.
  • French Biomedicine Agency. The Renal Epidemiology and Information Network Registry (REIN) [Internet]. [ cited 2019 Feb 6]. Available from: https://www.agence-biomedecine.fr/Le-programme-REIN.
  • Besarab A, Dalton CL. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients. Nephrol. Nurs. J. J. Am. Nephrol. Nurses Assoc. 2001;28:429–434.
  • Bailie GR, Larkina M, Goodkin DA, et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 2013;28:2570–2579.
  • Macdougall IC, White C, Anker SD, et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N. Engl. J. Med. 2019;380:447–458.
  • Mikhail AI, Schön S, Simon S, et al. A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO). BMC Nephrol. 2019;20:13.
  • Hofman JMG, Eisenga MF, Diepenbroek A, et al. Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients. BMC Nephrol. 2018;19:242.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.